Clinical Review Report: sarilumab (Kevzara) [Internet]

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May.


The objective of this report is to provide a systematic review of the beneficial and harmful effects of sarilumab for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs).

[Table: see text]

Publication types

  • Review